Literature DB >> 1552337

Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.

S S Rosenfeld1, J M Hoffman, R E Coleman, M J Glantz, M W Hanson, S C Schold.   

Abstract

Primary CNS lymphoma is a rare and highly malignant primary brain tumor. Ten patients with biopsy-proven primary CNS lymphoma were studied with 18F-2-fluoro-2-deoxy-D-glucose (FDG) and positron emission tomography (PET) to demonstrate the findings in patients with this tumor. The accumulation of FDG in primary CNS lymphoma is similar to that seen in anaplastic gliomas and is significantly more prominent than in low grade astrocytomas (p = 0.001). Steroid therapy substantially reduced the amount of FDG uptake in the one case studied both before and after its administration. The difference in FDG uptake between steroid-treated and untreated cases of primary CNS lymphoma, however, did not reach statistical significance (p = 0.40). Primary CNS lymphoma, like gliomas, suppresses the metabolism of both contiguous and distant but functionally linked areas of the brain. This study thus shows that the metabolic behavior of primary CNS lymphoma, as monitored by FDG-PET, resembles that of malignant glial tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1552337

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  27 in total

1.  FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.

Authors:  H Palmedo; H Urbach; H Bender; U Schlegel; I G H Schmidt-Wolf; A Matthies; M Linnebank; A Joe; J Bucerius; H-J Biersack; H Pels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-12       Impact factor: 9.236

2.  Delayed [(18)F]FDG PET imaging of central nervous system lymphoma: is PET better than MRI?

Authors:  Christian Jeanguillaume; Gilles Metrard; Hervé Rakotonirina; Olivier Morel; Cécile Berthelot; Tanguy Blaire; Francis Bouchet; Sylvie Giraud; Franck Lacoeuille; Aurélie Cahouet; Malgorzata Truchan-Graczyk; Charles Foussard; Jean Jacques Lejeune
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-19       Impact factor: 9.236

3.  Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma.

Authors:  Yoshiro Kawase; Yuka Yamamoto; Reiko Kameyama; Nobuyuki Kawai; Nobuyuki Kudomi; Yoshihiro Nishiyama
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

4.  Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma.

Authors:  Yoshihiro Nishiyama; Yuka Yamamoto; Toshihide Monden; Yasuhiro Sasakawa; Nobuyuki Kawai; Katashi Satoh; Motoomi Ohkawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-29       Impact factor: 9.236

5.  18F-FDG PET/CT in primary brain lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Mattia Bertoli; Raffaele Giubbini; Francesco Bertagna
Journal:  J Neurooncol       Date:  2017-11-17       Impact factor: 4.130

Review 6.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

7.  Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment.

Authors:  Nobuyuki Kawai; Hai-Ning Zhen; Keisuke Miyake; Yuka Yamamaoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  J Neurooncol       Date:  2010-11       Impact factor: 4.130

Review 8.  Central nervous system lymphoma: characteristic findings on traditional and advanced imaging.

Authors:  I S Haldorsen; A Espeland; E-M Larsson
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-08       Impact factor: 3.825

Review 9.  Positron emission tomography in patients with primary CNS lymphomas.

Authors:  U Roelcke; K L Leenders
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

Review 10.  Limitations of PET for imaging lymphoma.

Authors:  Sally F Barrington; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.